Genetic analysis of familial Alzheimer's disease has revealed that mutations in the g-secretase enzyme presenilin promote toxic Ab secretion; however, presenilin mutations might also influence tau hyperphosphorylation and neurodegeneration through g-secretaseindependent mechanisms. To address this possibility and determine whether other components of the g-secretase complex possess similar regulatory functions, we analyzed the roles of presenilin, nicastrin, and aph-1 in a Drosophila model for tau-induced neurodegeneration. Here, we show that presenilin and nicastrin prevent tau toxicity by modulating the PI3K/Akt/GSK3b phosphorylation pathway, whereas aph-1 regulates aPKC/PAR-1 activities. Moreover, we found that these transmembrane proteins differentially regulate the intracellular localization of GSK3b and aPKC at cell junctions. Inhibition of g-secretase activity neither interfered with these kinase pathways nor induced aberrant tau phosphorylation. These results establish new in vivo molecular functions for the three components of the g-secretase complex and reveal a different mechanism that might contribute to neuronal degeneration in Alzheimer's disease.
Introduction
Abnormal protein aggregation is a common characteristic of many neurodegenerative disorders. Alzheimer's disease (AD) is a classic example in which brains of affected individuals exhibit extracellular accumulation of Ab peptide because of aberrant proteolytic cleavage of the membrane bound amyloid precursor protein (APP) as well as intracellular aggregates of abnormally phosphorylated tau (Lee et al., 2001) .
Genetic analysis of early onset familial AD (FAD) has revealed that the pathological accumulation of Ab is due to mutations in APP or in the APP-cleavage enzyme presenilin , resulting in increased production of the more amyloidogenic Ab forms, termed Ab1-42 (Tanzi and Bertram, 2001) . Affected individuals also exhibit neurofibrillary tangles (NFT), leading to the proposal that Ab peptide accumulation triggers tau hyperphosphorylation and neuronal death in AD (Hardy and Selkoe, 2002) . Consistent with this idea, the induction of amyloid deposits in transgenic mice precedes and promotes NFT formation (Gotz et al., 2001; Lewis et al., 2001; Oddo et al., 2003) , whereas immunotherapeutic or pharmacological clearance of amyloid plaques suppresses early-stage tau lesions (Oddo et al., 2004) . Moreover, neurons from mice lacking tau are insensitive to b-amyloid-mediated toxicity (Rapoport et al., 2002) .
Although there is a large body of evidence supporting the amyloid cascade in Alzheimer's disease (Hardy and Selkoe, 2002; Scheuner et al., 1996; St George-Hyslop and Petit, 2005; Tanzi and Bertram, 2005) , the neurodegeneration typical of this disease can occur independently of extracellular amyloid. Certain cases of FAD are characterized by abundant NFT in the absence of amyloid plaques (Dermaut et al., 2004) , suggesting that increased Ab secretion may not be the only contributing factor to the onset of disease. In support of this view are the neurological phenotypes observed in presenilin 1 and presenilin 2 brain-specific conditional knockout mice. These animals exhibit memory defects, synaptic dysfunction, increased tau phosphorylation, and neurodegeneration without amyloid production (Feng et al., 2004; Saura et al., 2004) . Thus, at least some cases of dementia could be due to aberrant tau phosphorylation induced by presenilin malfunction. In this scenario, presenilin, alone or as part of the g-secretase complex with nicastrin, aph-1 and pen-2 (De Strooper, 2003) , might regulate the intracellular phosphorylation pathways that converge upon tau. Indeed, recent work has shown that presenilin promotes cadherin/PI3K recruitment and prevents GSK3b-mediated tau phosphorylation in vitro (Baki et al., 2004) . It is not known, however, whether a similar mechanism influences tau toxicity in vivo or what role other g-secretase components play in tau-induced neurodegeneration. To address these questions, we examined the effects of gene dosage alterations in presenilin (psn), nicastrin (nct), and aph-1 with a Drosophila transgenic model for tau-induced neurodegeneration (Jackson et al., 2002; Wittmann et al., 2001 ). 
Results

Reduced Presenilin Function In Vivo Leads to Tau Hyperphosphorylation and Neurodegeneration
Compared to the wild-type fly eye, expression of htau under the eye-specific promoter glass (hereafter gl-htau) produces a mild disorganization of the retina that is evident as a roughened exterior eye surface (Figures 1A and 1B) (Jackson et al., 2002) . This phenotype is dramatically enhanced when one copy of presenilin (psn) is removed, as found with two different null alleles of psn ( Figures 1C and 1D ) . Eyes are significantly reduced in size, and fused or disordered ommatidia cover >80% of the eye surface. Longitudinal sections labeled with the photoreceptor-specific antibody 24B10 (Zipursky et al., 1984) revealed that expression of htau alone leads to mild disorganization of the internal retinal morphology (Figures 1F and 1G) , whereas the retinas of gl-htau/psn B3 and psn C4 heterozygous flies displayed dramatic defects including reduced photoreceptor layer depth, decomposition of the basement membrane, and increased neuronal cell loss (Figures 1H and 1I) .
To determine if these cellular defects correlated with abnormal modification of tau, we analyzed tau phosphorylation status in gl-htau/psn flies. Western blotting of Drosophila head extracts with AT8 and 12E8 antibodies, which detect two distinct AD-related tau epitopes, revealed that reduction in psn increases AT8 but not 12E8 signal ( Figure 1K ). Reactivity to antibodies PHF1 and AT100, which recognize abnormally phosphorylated tau in pretangle paired helical filaments and fully formed neurofibrillary tangles, respectively, (Seubert et al., 1995; Hernandez et al., 2003; Lovestone et al., 1994; Lucas et al., 2001) , revealed a dramatic increase in tau phosphorylation at these epitopes as well ( Figure 1K ). To confirm these differences in the phosphorylation pattern of tau, we analyzed each genotype by an immunocytochemical approach. Tangential sections of adult retinas labeled with the 7.51 antibody against total tau did not reveal any modifications in tau expression when one copy of psn was removed ( Figures  S1D-S1F ). In contrast, the AT100 antibody epitope showed dramatic changes in intensity and distribution (Figures S1A-S1C), confirming that htau is abnormally modified when psn function is genetically reduced. To examine whether these modifications affect htau intracellular solubility, we performed sarcosyl extractions to monitor levels of filamentous tau. Compared to control gl-htau flies, tau is more insoluble in psn heterozygous flies ( Figure 1L ), suggesting that htau undergoes alterations similar to those observed in AD.
To prove that the changes in tau phosphorylation were a consequence of psn loss and not due to genetic background effects, we performed a genetic rescue experiment by expressing full-length psn under the GMR promoter in gl-htau/psn B3 transheterozygous flies. This ectopic psn expression largely suppressed the htau-mediated neurodegeneration (Figures 1E and 1J) and reduced htau phosphorylation levels at the AT8, AT100, and PHF1 sites ( Figure 1M ). Thus, endogenous levels of psn are required to prevent abnormal tau phosphorylation in vivo. Intriguingly, the data suggest that the psn regulatory effect is specific for certain phosphorylation pathways, as reflected by the absence of increased 12E8 immunoreactivity (Figure 1K ), rather than a global upregulation of tau kinase activities.
Tau Hyperphosphorylation Induced by Presenilin Reduction Requires GSK3b but Not PAR-1 Activity Abnormal phosphorylation of tau at the AT8, PHF1, and AT100 epitopes in psn heterozygous flies suggests that GSK3b might be the kinase regulated by psn. Previous in vitro studies showed that psn regulates GSK3b activity and prevents tau hyperphosphorylation through activation of the PI3K/Akt pathway (Baki et al., 2004) . We therefore analyzed whether mutations in psn increase the activity of shaggy, the Drosophila homolog of human GSK3b (Siegfried et al., 1992) , and whether mutations in this kinase suppress psn-induced tau toxicity. First, we expressed shaggy with the eye-specific GMR promoter (GMR-UAS-sgg) (Jackson et al., 2002; Nishimura et al., 2004) , which produces a mild retinal degeneration phenotype ( Figure 2A ; see Figure 1A for comparison). This phenotype was strongly enhanced by removal of one copy of psn, suggesting that the activity of the shaggy kinase was further increased ( Figure 2B ). We monitored the phosphorylation status of shaggy under different psn gene dosages with phospho-specific antibodies that recognize either the phospho-tyrosine-216 residue ) in the active kinase (Figures S2A and S2B) or the phosphorylated inhibitory serine-9 residue (anti-GSK3b-pS 9 ) (Matsubayashi et al., 2004; Nusse, 1997 ). An increase in shaggy activation was observed in heterozygous psn flies compared to wildtype ( Figure 2F , anti-GSK3b-pY 216 antibody). A concomitant decrease was detected at the inhibitory serine-9 epitope (data not shown). Removing one copy of psn in GMR-UAS-sgg flies led to a dramatic reduction in the GSK3b-pS 9 signal, confirming the increased activation of shaggy in the psn heterozygous background (Figure 2F) . Rescue experiments corroborated the role of psn in regulating shaggy activity as shown by suppression of the GMR-UAS-sgg phenotype upon psn transgene expression (Figures 2B and 2C) . Transgenic psn expression also elevated shaggy phosphorylation on inhibitory serine-9 and reduced signal at the GSK3b-pY 216 site in the activation loop ( Figure 2F ), demonstrating that psn inhibits shaggy activation.
Next, we analyzed whether reducing shaggy activity suppresses psn-induced neurodegeneration. Removing one copy of shaggy from gl-htau/psn transheterozygous flies suppressed the psn mutation-induced enhancement of the gl-htau eye phenotype ( Figure 2D ; compare to Figures 1C and 1D and see Figure S3A for quantitative analysis). The psn transheterozygous flies lacking one dose of shaggy showed significant reductions in tau phosphorylation at the cytotoxic epitopes AT100 and PHF1 ( Figure 2G ). On the other hand, removing one copy of PAR-1, the kinase responsible for tau phosphorylation at the 12E8 epitope (Nishimura et al., 2004) , did not ameliorate the effects of the psn mutation (Figure 2E ), indicating that psn regulation of shaggy is specific. We also explored whether Akt (the specific kinase for the serine-9 epitope) and its activator PI3K are involved in the psn/shaggy/tau phosphorylation pathway in vivo. We reasoned that if this is the case, lower activity ) demonstrating increases at the AT8, PHF1, and AT100, but not 12E8 epitopes compared to control gl-htau flies. Immunoblotting with 7.51 antibody against total htau confirms equal sample loading. (L) Sarcosyl-insoluble tau levels in gl-htau transgenic flies with reduced gene dosages of individual g-secretase components in head homogenates probed with the 7.51 antibody. (M) Suppression of psn mutant-induced htau hyperphosphorylation by transgenic psn expression. Expression of psn under GMR-GAL4 control in w; gl-htau/+; GMR-UASpsn+14/psn B3 reduces tau phosphorylation at AT8, AT100, and PHF1 epitopes compared to w; gl-htau/+; psn B3 /+ flies. Antibody 7.51 was used as the loading control. Histograms represent quantitative analysis of the corresponding blots in (K)-(M). Scale bars: (A-E), 100 mm; (F-J), 20 mm. Mean 6 SEM, p < 0.001.
of the PI3K/Akt pathway should increase tau toxicity, whereas exogenous PI3K/Akt expression might suppress the neurodegeneration caused by psn gene dose defects. As predicted, expression of a dominantnegative form of PI3K or removal of one copy of Akt increased tau-mediated neurotoxicity (Figures 2H and 2I ; compare to Figure 1B and see Figure S3B for quantification). Conversely, ectopic expression of PI3K and Akt transgenes dramatically suppressed the phenotype induced by heterozygosity for psn (Figures 2J and 2K ; Figure 1C for comparison) as well as hyperphosphorylation of htau ( Figure 2L ). In addition, probing the phosphorylation status of Akt at serine-473, a site modulated by PI3K (Baki et al., 2004) , revealed that it is underphosphorylated in psn heterozygous flies, suggesting that psn is required for full activation of the PI3K/Akt pathway ( Figure 2M ). Taken together, our results show that psn counteracts tau phosphorylation in vivo through the PI3K/Akt/GSK3b pathway. Our third experimental approach toward understanding how psn controls shaggy/GSK3b activity in vivo involves examining the spatial distribution of the kinase in the presence or absence of psn. Relocalization of the shaggy kinase from the membrane to the cytoplasm might be indicative of its differential modulation in certain genotypes, with implications for tau phosphorylation. In wild-type third instar larval imaginal eye discs, shaggy labeling is most evident in discrete vesicles close to the cell cortex in both neurons and epithelial cells. In contrast, in psn homozygous mutant eye clones, the kinase adopts a much more diffuse, intracytoplasmic distribution (Figures 2N and 2O) . We determined that the intracellular distribution of the Drosophila b-catenin homolog armadillo (another substrate of shaggy) was not affected by psn mutations (Figures 2P and 2Q) , indicating that the effect observed on shaggy localization is specific and cannot be attributed to a general defect in cell survival or apicobasal polarity.
The Regulation of Tau Kinase Pathways Does Not Require the Aspartyl Protease Function of Presenilin
To explore the relevance of our findings to AD, we examined whether familial Alzheimer's disease (FAD)-linked mutations interfered with the regulatory effects of psn described above. Toward this aim, we analyzed the capacity of a psn FAD mutant allele with a deletion in exon 9 (psnDE9) to suppress the enhanced tau toxicity induced by loss of one copy of psn. Two different insertions of the psnDE9 FAD mutation expressed under the GMR promoter failed to rescue the gl-htau/psn phenotype compared to the wild-type psn transgene (Figures 3A and 3B; compare to Figure 1E ; Figure S3C for quantification). Unexpectedly, analogous expression of catalytically inactive alleles of psn (Asp-257 or Asp-385) supports almost complete rescue of the psn-induced neurodegeneration ( Figures 3C and 3D ). These different outcomes were verified at the molecular level for the relevant kinases. Compared to the psn wild-type allele, psnDE9 failed to promote Akt phosphorylation or to phosphorylate shaggy at the Akt-specific epitope serine-9 and also did not prevent tau hyperphosphorylation ( Figure 3E ). However, the catalytically inactive psn alleles activate the PI3K/Akt pathway and suppress tau phosphorylation as efficiently as wild-type ( Figure 3E ). These data suggest that FAD mutations in psn may promote tau hyperphosphorylation by g-secretase-independent mechanisms.
To further test this idea, we suppressed g-secretase activity by exposing gl-htau-expressing flies to well-characterized g-secretase inhibitors throughout development. To confirm that the drugs effectively blocked psn aspartyl protease activity, we utilized a transgenic readout to assess g-secretase cleavage in vivo. This system relies on a transmembrane form of human APP (C99) fused to the transcriptional activator GAL4-VP16 (GV), which induces expression of a nuclear UAS-cd8-GFP reporter gene after intramembrane g-secretase cleavage of the C99-GAL4-VP16 fusion (Struhl and Adachi, 2000) . These flies, also bearing the gl-htau transgene (referred to as gl-htau/Ab-GV, UAS-cd8-GFP), exhibit robust gsecretase-dependent expression of GFP ( Figure 3F ; see Experimental Procedures). When treated with the g-secretase inhibitor DAPT (Micchelli et al., 2003) , their GFP signal was strongly reduced ( Figure 3G ). Similar effects were obtained with a second g-secretase inhibitor, Compound E (data not shown). Western blot analysis of extracts from DAPT/Compound E-treated and untreated gl-htau/Ab-GV, UAS-cd8-GFP fly heads revealed that g-secretase inhibition had no effect on tau phosphorylation or the activation status of shaggy ( Figure 3H ). These results /+ transheterozygous flies, as revealed by increased phosphorylation at the GSK3b-pY 216 activation loop epitope (see also Figure S1 ) and decreased inhibitory phosphorylation at serine-9 detected by GSK3b-pS 9 antibody in psn heterozygous w; +/+; GMR-UAS-sgg/psn B3 flies relative to control w; +/+; GMR-UAS-sgg/+ flies. Conversely, psn transgenic expression antagonizes shaggy activity as revealed by decreased phosphorylation of the activation loop and increased GSK3b-pS 9 signal in w; GMR-UAS-sgg/UAS-psn+14. Tubulin serves as the loading control. (G) Shaggy is responsible for htau hyperphosphorylation at AT100 and PHF1 epitopes in psn heterozygous flies as deduced by comparing tau phosphorylation in w; gl-htau/+, w/sgg 1 ; gl-htau/+, w; gl-htau/+; psn 
further confirm a regulatory activity of psn distinct from its known aspartyl protease function.
Loss-of-Function Mutations in Nicastrin and aph-1 Induce Tau Hyperphosphorylation and Neurodegeneration
Our previous results indicating that psn possesses g-secretase-independent regulatory capacities toward tau led us to ask whether other components of the g-secretase complex exert similar functions. We performed a series of genetic interaction experiments with null mutations of nct or aph-1 in conjunction with gl-htau. Figures 4A-4D show the eye phenotypes produced by removing one copy of nct or aph-1 in gl-htau expressing flies (see Figure 1B for control). Two different alleles for nicastrin (nct A7 and nct J1 ) or aph-1 (aph-1 D35 and the aph-1 deficiency Df[2L]N6) were utilized for this experiment (Hu and Fortini, 2003; Hu et al., 2002) . From the reduced size and severely roughened appearance of the eye surface, it is evident that mutations in either nct or aph-1 strongly enhance the neurodegenerative phenotype of htau (see Figure S3D for quantification). To investigate whether the internal retinal morphology is correlated with the degree of neurodegeneration apparent from the external eye phenotype, we performed histological analysis. Compared to control flies (see Figure 1G ), both nct alleles enhanced the gl-htau phenotype ( Figures 4E and 4F ), whereas aph-1 mutant-induced enhancement of the phenotype was more modest (Figures 4G and 4H) .
To determine if these genetic interactions were accompanied by changes in htau phosphorylation, we performed biochemical studies similar to those described above for psn (cf. Figure 1K ). Interestingly, we observed that heterozygous nct or aph-1 mutations cause different effects on tau phosphorylation ( Figure 4I ). Although both nct and aph-1 hyperphosphorylate tau at the PHF1 antibody epitope, mutations in nct enhance htau phosphorylation at the AT8 site, whereas those in aph-1 preferentially increase phosphorylation at the 12E8 and AT100 sites. These modifications increase the cytoplasmic insolubility of tau as reflected by changes observed in sarcosyl extraction experiments ( Figure 1L ). Genetic rescue experiments confirmed the specificity of these histological and biochemical findings. Expression of wild-type nct or aph-1 transgenes in gltau/nct or gltau/ aph-1 transheterozygous flies strongly suppressed both the aberrant retinal phenotypes and the abnormal induction of tau phosphorylation ( Figures 4J-4N ). Taken together, these results demonstrate that reductions in nct and aph-1, like psn, induce abnormal tau hyperphosphorylation and enhanced neurotoxicity. Given that pharmacological inhibition of g-secretase activity did not modify the tau phosphorylation pattern, nct and aph-1 also presumably regulate these phosphorylation pathways through g-secretase-independent mechanisms.
Drosophila Nicastrin and aph-1 Prevent Tau Toxicity through the Shaggy/GSK3b and PAR-1 Signaling Pathways, Respectively The biochemical data in Figure 4I suggests that nct and aph-1 dosage changes result in qualitative differences with respect to the particular htau phospho-epitopes affected. Heterozygous mutations in nct enhanced htau phosphorylation at epitopes recognized by the AT8 and PHF1 antibodies, suggesting that, as with psn, shaggy/GSK3b is the relevant kinase, whereas the aph-1 mutation resulted in increased phosphorylation at the PAR-1-specific 12E8 epitope. To determine if these kinases are differentially upregulated in the nct and aph-1 genotypes, we examined whether reductions in shaggy or PAR-1 activity suppressed the htau phenotypes produced by nct and aph-1 gene dose changes. Removing one copy of shaggy strongly suppressed the phenotype observed in gl-htau/nct flies ( Figure 5A ; compare to Figure 4A ). Interestingly, a similar gene-dose reduction in shaggy failed to suppress the neurodegeneration induced by aph-1 ( Figure 5B ). Conversely, eliminating one copy of PAR-1 strongly suppressed this aph-1-associated phenotype ( Figure 5C ; compare to Figure 4C ) without any effect on neurodegeneration induced by nct ( Figure 5D ; see Figure S3E for quantification).
To further explore these results, we analyzed whether nct and aph-1 modulate the activity of shaggy and PAR1 in vivo. We exogenously expressed these kinases with the eye-specific GMR promoter, utilizing the GMR-UAS-sgg transgene (see above) and a GMR-UAS-PAR-1 transgene (Jackson et al., 2002; Nishimura et al., 2004) . A gene-dose reduction in nct strongly enhanced the phenotype of the shaggy-expressing flies ( Figure 5E , compare to Figure 2A) , whereas a similar deficiency in aph-1 had no effect ( Figure 5F ). Consistent with these observations, ectopic expression of the aph-1 transgene did not rescue the GMR-UAS-sgg/nct heterozygous phenotype or suppress the effect of shaggy expression alone ( Figure 5G and Figure S3F ).
An analogous approach utilizing PAR-1 revealed that mutations in aph-1 but not nct or psn modified the phenotype produced by expression of this kinase. GMR-UAS-PAR-1-expressing flies display a rough eye phenotype characterized by the absence of interommatidial bristles, a glazed eye surface, and a mild reduction in eye size ( Figure 5I ). When one copy of aph-1 was removed from this genetic background, the eye phenotype was dramatically enhanced, as evinced by the severely reduced size of the eye ( Figure 5J) . A similar phenotype was observed with the aph-1 deficiency (data not shown). In contrast to aph-1, heterozygous mutations in nct or psn failed to modify the PAR-1 expression phenotype ( Figures 5K and 5L) . Consistent with these findings, expression of nct or psn transgenes was unable to rescue the aph-1 dosage effect on this PAR-1-induced (E) Western blot analysis showing that psnDE9 does not activate Akt or inhibit GSK3b and is unable to suppress tau hyperphosphorylation at the AT8 epitope. Tubulin serves as the loading control. 5N , and 5O; see Figure 5J for comparison).
To validate these genetic interactions at the molecular level, we analyzed the phosphorylation status of these kinases in the different genotypes. Western blot analysis of wild-type, nct, and aph-1 heterozygous mutant head extracts with the anti-GSK3b-pY 216 antibody revealed modest yet reproducible increases in activated shaggy in nct heterozygous flies, but not in aph-1 mutant flies (Figure 5P) . A similar analysis utilizing the anti-GSK3b-pS 9 antibody in shaggy-expressing flies showed that mutations in nct, but not in aph-1, reduced the phosphorylation levels at the inhibitory serine-9 ( Figure 5P ). These modifications were rescued by ectopic expression of the nct transgene but not the aph-1 transgene, confirming that nct regulates the activation status of shaggy in vivo.
To evaluate whether mutations in aph-1 increase PAR-1 activity, we utilized two different approaches. First, we analyzed the phosphorylation status of PAR-1 at the conserved inhibitory threonine-595 (PAR-1T595) (Hurov et al., 2004) (Figure S2C ). Second, we analyzed htau phosphorylation levels at an epitope specifically phosphorylated by PAR-1 and recognized by the 12E8 antibody. Gene-dose defects in aph-1, but not in nct or psn, decreased phosphorylation levels of PAR-1 at the T595 site indicating that the kinase is more active in the absence of aph-1. This labeling was restored by introduction of the aph-1 transgene, but not by introduction of nct or psn transgenes ( Figure 5Q ). In agreement with these results, aph-1 heterozygous mutant flies exhibited increased 12E8 reactivity compared to gl-htau control flies, which was suppressed by the aph-1 transgene ( Figure 4N ). Taken together, these results demonstrate that nct and aph-1 suppress tau hyperphosphorylation via two distinct pathways involving shaggy/GSK3b and PAR-1, respectively.
Nicastrin Regulates Shaggy Activity and Tau
Phosphorylation via the PI3K/Akt Pathway The experiments described above suggested that nct and psn might share a common regulatory pathway. To address this possibility, we analyzed whether PI3K or Akt transgenic expression rescues the phenotype observed in gl-htau/nct heterozygous flies. Increased levels of PI3K expression completely rescued the toxicity induced by removing one copy of nct ( Figure 6A ; compare to Figures 4A and 4B) . Furthermore, this effect is strictly dependent on PI3K activity because a similar attempt, with a ''kinase dead'' form of the enzyme, failed to rescue the phenotype ( Figure 6B ). As expected, transgenic expression of two different activating alleles of Akt also suppressed the nct-mediated tau toxicity ( Figures 6C  and 6D) .
At the molecular level, we observed that mutations in nct but not aph-1 decreased the levels of Akt phosphorylation at the residue recognized by PI3K ( Figure 6E ), similar to the effect observed earlier for psn ( Figure 2M ). Moreover, ectopic expression of either PI3K or Akt led to a decrease in the level of tau phosphorylation at the GSK3b-related AT8 epitope ( Figure 6F ).
In addition, we found that nct is required and sufficient to maintain the proper localization of shaggy at the cell cortex. Shaggy is dramatically mislocalized in nct homozygous mutant eye clones compared to wild-type cells ( Figure 6G ). In nct mutant cells, shaggy adopted a more diffuse intracytoplasmic distribution. Although mutations in nct exhibit severe defects in photoreceptor differentiation because of impaired Notch signaling and cytoskeletal assembly (Ló pez-Schier and St Johnston, 2002), the specificity of the effect on shaggy localization can be inferred from the unaffected subcellular distribution of two other cortically distributed proteins, namely the b-catenin homolog armadillo and the aPKC kinase ( Figures 6H and 6I ). An opposing effect was observed upon expression of the nct transgene; higher levels of nct expression caused a dramatic accumulation of shaggy at the cell cortex ( Figure 6J ), whereas the distribution of PAR-1 was unaffected ( Figure 6K ). In sum, these data suggest that nct, like psn, suppresses tau phosphorylation through the PI3K/Akt/GSK3b pathway by promoting the proper compartmentalization of shaggy activity within the cell.
Aph-1 Suppresses Tau Hyperphosphorylation through the aPKC/PAR-1 Pathway
We have shown above ( Figure 5Q ) that modifications in aph-1 expression levels affect the phosphorylation status of PAR-1 at inhibitory threonine-595, a putative phosphorylated residue for the atypical phospho-kinase C (aPKC) (Hurov et al., 2004) . To test if aPKC is involved in aph-1-mediated PAR-1 repression, we analyzed first whether mutations in this kinase affect tau toxicity. Two different alleles of aPKC, a heterozygous loss-offunction mutant ( Figure 7A ) and a dominant negative form of the kinase (aPKC-DN) ( Figure 7B ), enhanced tau-mediated neurodegeneration. Moreover, the same aPKC mutants in combination with mutations in aph-1 increased the phenotypic effect on tau toxicity exerted by any of these single mutations (data not shown). Moreover, the aPKC mutants counteracted the genetic rescue of the gl-htau/aph-1phenotype mediated by aph-1 transgenic expression ( Figure 7C ), further implicating aPKC in the aph-1 mutant-induced tau toxicity.
To determine whether aph-1 modulates PAR-1 activity via aPKC, we performed an epistatic analysis with these genes. A reduction in gene dose levels of aPKC or Figures 7D-7F) . Furthermore, heterozygous mutations in aPKC increased tau phosphorylation levels at the PAR-1-specific epitope 12E8 and decreased the levels of antipT595-PAR-1 antibody labeling, indicating that PAR-1 was more active (Figures 7G and 7H) . From these results, we infer that aPKC activity is required to mediate the regulatory effect of aph-1 on PAR-1 function.
To gain more insight into the mechanism through which aph-1 regulates aPKC and PAR-1, we analyzed whether aph-1 influences the intracellular localization of these two kinases. Homozygous aph-1 mutant cell clones were generated at embryonic stages and the subcellular distributions of both aPKC and PAR-1 were evaluated in larval eye discs (see Experimental Procedures). In aph-1 mutant cells, the subcellular distribution of aPKC was strikingly altered ( Figure 7I ). The cortical localization of aPKC was lost within the clone area, indicating that aph-1 is required for the proper localization of the enzyme. Interestingly, analysis of the intracellular distribution of PAR-1 using an antibody that recognizes total PAR-1 protein, regardless of phosphorylated status, showed that within aph-1 mutant clones, the bulk pool of PAR-1was properly localized at the cell cortex (Figure 7J) . However, similar labeling using the phosphospecific anti-pT595-PAR-1 antibody revealed that this phosphorylated form of PAR-1 is no longer detected within aph-1 mutant cells, suggesting that aph-1 is required specifically for phosphorylation of PAR-1 on T595 or, alternatively, for the cortical accumulation of T595-phosphorylated forms of PAR-1 ( Figure 7K) . A complementary approach with anti-shaggy antibodies did not detect any differences in shaggy protein levels or its intracellular localization between wild-type and aph-1 mutant cells ( Figure 7L ).
To further evaluate the effects of aph-1 on the intracellular distribution of aPKC, we examined whether expression of the aph-1 transgene affected the intracellular localization of this kinase. Expression of aph-1 under the eye-specific GMR promoter caused an extraordinary concentration of p-T595-PAR-1 labeling at the cell cortex just beneath the plasma membrane ( Figure 7M ), whereas shaggy intracellular localization was not noticeably affected ( Figure 7N) . Collectively, these data show that aph-1 determines the localization of aPKC at the cell cortex and that this effect is necessary for aph-1-mediated regulation of PAR-1 activity and subsequent tau phosphorylation.
Discussion
A widely accepted view of AD pathogenesis, the ''amyloid cascade hypothesis,'' holds that the abnormal accumulation of Ab triggers an intracellular signaling cascade resulting in tau hyperphosphorylation, neurofibrillary tangle formation, and, ultimately, neuronal dysfunction and death (Hardy and Selkoe, 2002) . However, it appears that some cases of AD occur in the absence of b-amyloid triggering pathology. This idea is supported by the observation of FAD cases linked to loss-of-function mutations in psn that nonetheless exhibit tau hyperphosphorylation and neuronal degeneration (Dermaut et al., 2004; Marjaux et al., 2004) . To investigate nonamyloidogenic mechanisms that potentially contribute to AD pathogenesis, we utilized Drosophila melanogaster, a genetic model organism that possesses highly conserved psn and g-secretase components but no APP homologs capable of generating the Ab peptide (Luo et al., 1990) . We examined the effects caused by both gene dosage reductions and transgenic expression of individual fly g-secretase components and candidate tau kinases in a sensitized genetic assay, in which transgenic expression of human tau produces a uniform but easily modifiable retinal phenotype. This approach has been widely used in Drosophila to investigate basic signaling pathways as well as neurodegenerative disease mechanisms (Bilen and Bonini, 2005; Zoghbi and Botas, 2002) .
Using the Drosophila transgenic model, we demonstrate that psn and its cofactors nct and aph-1 have an essential role in preventing tau hyperphosphorylation via regulation of independent PI3K/Akt/GSK3b and aPKC/PAR-1 pathways. These conclusions are supported by the following observations: (1) gene dosage reduction in psn and nct result in reduced levels of phosphorylated Akt and GSK3b at the inhibitory serine-9, accompanied by increased tau phosphorylation. On the other hand, aph-1 heterozygous flies exhibit low levels of phosphorylated PAR-1 at the inhibitory threonine-595 and increased tau phosphorylation at the PAR-1-derived epitope 12E8; (2) ectopic expression of (C and D) Removing one dose of PAR-1 suppresses the aph-1 mutant-induced tau eye phenotype in w; aph-1 D35 /par1 W3 ; gl-tau/+ but does not modify the nct mutation-induced tau phenotype in w; par1 W3 /+; gl-tau/nct J1 (D). (E and F) Removing one dose of nct in GMR-UAS-sgg/nct J1 , but not aph-1 in GMR-UAS-sgg/aph-1 D35 flies (F), enhances the shaggy-induced rough eye phenotype (compare to GMR-UAS-sgg in Figure 2A , GMR-UAS-sgg/aph-1 D35 flies, GMR-UAS-sgg/UAS-nct, and GMR-UAS-sgg/UAS-aph-1. Anti-GSK3b antibodies are described in the legend to Figure 2 ; tubulin serves as the loading control; blot quantification histograms are at right. (Q) Western blot analysis of GMR-UAS-par1/UAS-aph-1, GMR-UAS-par1/UAS-nct, and GMR-UAS-par1/aph-1 D35 head extracts with the PAR-1T595 antibody, which recognizes PAR-1 phosphorylated at the inhibitory threonine-595; tubulin serves as the loading control; blot quantification histograms are at right. Scale bars: (A)-(O), 100 mm. Mean 6 SEM, p < 0.001.
psn, nct, and aph-1 specifically rescues these phenotypes; (3) reduction in GSK3b activity prevents psn and nct-mediated tau toxicity, whereas increased activity of PI3K or Akt suppresses it; (4) reduction in PAR-1 function prevents aph-1-induced neurodegeneration, whereas lowering the activity of aPKC, the putative PAR-1 inhibitory kinase, counteracts this effect, implicating a distinct regulatory pathway for aph-1; and (5) simple overexpression of psn, nct, or aph-1 prevents htau-induced neurodegeneration in the htau transgenic model ( Figure S4 ). Although overexpression of wild-type psn has previously been shown to cause low levels of developmental apoptosis in the fly retina, attributable to dominant-negative interference with Notch signaling , these effects are strongly outweighed by the neuroprotective effects of psn on tau hyperphosphorylation. What is the underlying biochemical mechanism for these effects? Through studies on the subcellular distributions of the relevant kinases in various genetic conditions, we found that psn and nct control the intracellular distribution of GSK3b, whereas aph-1 is required to preserve the normal distribution of aPKC and the phosphorylated form of PAR-1 at the cell cortex. It is unclear whether these effects involve direct associations between psn, nct, aph-1, and the identified kinases or if they are mediated by other proteins. Interestingly, our rescue studies indicate that the cytoplasmic loop region of psn, which is altered in the DE9 mutant, is functionally important in terms of tau phosphorylation, and this loop region is known to interact with several putative psnassociated factors (Koo and Kopan, 2004; Menendez, 2004) .
These kinase-regulatory functions of psn, nct, and aph-1 are apparently independent of their traditional role in g-secretase cleavage, as deduced from the fact that the well-characterized aspartyl mutants of psn, which lack catalytic protease activity, are still functional with respect to regulation of tau phosphorylation. In support of this concept, drug treatment of flies with two different g-secretase aspartyl protease inhibitors failed to affect tau phosphorylation or the activation status of shaggy (see also Baki et al. [2004] ). The equivalent phenotypes we observed for psn and nct loss-of-function alleles are also intriguing. It has been shown previously that Drosophila nct confers stability to mature psn (Chung and Struhl, 2001; Hu et al., 2002; Ló pezSchier and St Johnston, 2002) , raising the possibility that the tau hyperphosphorylation seen upon reducing nct activity could actually be due to a secondary effect on psn accumulation.
The modulatory effects psn, nct, or aph-1 on the tau kinase pathways observed in our Drosophila studies might be of particular relevance to the pathogenesis of Alzheimer's disease. Over 100 different FAD mutations in PS1 and PS2 have now been identified, all of which cause disease in an autosomal dominant manner (Hashimoto et al., 2004; St George-Hyslop and Petit, 2005) . Although it remains controversial whether this autosomal dominant behavior reflects a toxic ''gain-of-function'' activity or a haploinsufficient dosage-related mechanism, several observations indicate that FAD mutations in presenilin are loss-of-function mutations in some respects. When various FAD mutations were genetically assessed with multiple independent mouse and nematode transgenic models, they were found to act as partial loss-offunction alleles (Baumeister et al., 1997; Davis et al., 1998; Levitan et al., 1996; Qian et al., 1998) . Moreover, a PS1 FAD mutation has been identified that truncates the protein and therefore most likely causes disease through a haploinsufficient mechanism involving loss of one functional gene copy (Tysoe et al., 1998) . If, as these findings indicate, loss of one dose of presenilin contributes to Alzheimer's disease pathogenesis, the fact that similar gene dosage reductions in presenilin and other g-secretase components lead to dysregulation of tau kinase pathways raises the possibility that these effects might be causally involved in disease development. This idea is consistent with our observation that an FAD-like presenilin mutant transgene, psnDE9, is unable to rescue the tau phenotypes associated with psn haploinsufficiency. Our findings also agree with a previous study showing that three different PS1 FAD mutations, including DE9, have effects on neurite growth and tau phosphorylation counter to those of wild-type PS1 (Pigino et al., 2001 ). Nevertheless, it should be noted that we cannot exclude the possibility that an unknown function of these g-secretase components, perhaps related to cytoskeletal scaffolding processes or protein trafficking, is affected by the gene dosage manipulations and is responsible for the observed effects on tau kinase pathways. Further investigation will be required to clarify this issue, particularly in view of the apparent lack of a requirement for the aspartyl protease activity of g-secretase in regulating tau phosphorylation.
In conclusion, these data identify distinct roles for presenilin and its cofactors nicastrin and aph-1 in the organization of intracellular junctions. Furthermore, we found that they protect against abnormal tau phosphorylation levels in vivo through g-secretase-independent regulation of the PI3K/Akt/GSK3b and aPKC/PAR-1 Our results suggest that therapies aimed at treating or preventing Alzheimer's disease through suppression of g-secretase activity should also take into account possible alterations in the levels of g-secretase complex components, which might lead to potentially harmful effects on tau metabolism in neuronal target tissues. Moreover, the experimental paradigm described here may serve as a useful entry point to identify genes or compounds capable of interfering with the deleterious activities of GSK3b and PAR-1 in tau hyperphosphorylation and neurotoxicity.
Experimental Procedures
Genetics PAR-1 W3 , UAS-PAR1, and APP-GV flies were generous gifts from Drs. Daniel St. Johnston, Bingwei Lu, and Gary Struhl. The ey-FLP system was used to generate homozygous mutant eyes (Newsome et al., 2000) . For heat-shock-induced recombinase, 24 hr old first instar larvae were treated for 30 min at 38ºC.
Histology and Immunohistochemistry
Cryostat sectioning (10 mm) of adult heads was performed as described previously (Jackson et al., 1998) . Immunolabeling with 24B10 (1:50; Developmental Studies Hybridoma Bank) and AT100 antibody were followed by secondary antibody conjugated to horseradish peroxidase (HRP) and Alexa-red (1:100; Molecular Probes).
Third instar larvae were examined with the following antibody dilutions: 24B10 (1:50), GSK3b-pY 216 (1:100; Biosource International), armadillo (1:50; Developmental Studies Hybridoma Bank), PAR-1T595 (1:50), aPKC (1:100; Santa Cruz Biotechnology), LacZ (1:500; ICN), and MARK (1:100) with an Alexa-conjugated secondary antibody (1:100). Images were collected using a Leica confocal microscope.
Quantification of Adult Eye Phenotypes
Adult eye roughness was calculated as a percentage of the total eye surface by scoring images obtained by high-resolution light microscopy (w200 eyes scored/genotype).
Western Blot Analysis
Tau phosphorylation status was analyzed in adult fly heads homogenized in lysis buffer (10 mM Tris/HCl [pH 7.4], 150 mM NaCl, 5 mM EDTA, 5 mM EGTA, 10% glycerol, 50 mM NaF, 1 mM NaVOF, 5 mM DTT, 4 M Urea, and protease inhibitors). Proteins were resolved by 10% SDS-PAGE and probed with the following antibodies: 7.51 (1:100; provided by Dr. C.M. Wischik), 12E8 (1:1000; Elan Pharmaceuticals, provided by Dr. Seubert), AT8 (1:500; Innogenetics), tau1 (1:10000; Chemicon), PHF-1 (1:100; provided by Dr. P. Davies), and AT100 (1:100; Innogenetics). Shaggy/GSK3b activation status was monitored using GSK3b-pY 216 (1:1000; Biosource International) and GSK3b-pS 9 (1:1000; Cell Signaling Technology). Activation status of Akt and PAR1 was determined with p-Akt (1:1000; Cell Signaling) and p-PAR1-T595 (1:1000) (see Hurov et al. [2004] ). An antibody against a-tubulin (1:5000; Amersham) was used for loading controls. Sarcosyl extraction was performed as previously described (Wittmann et al., 2001) . Western blots were incubated with HRPlabeled secondary antibodies (Amersham) and signals quantitated by densitometry of autoradiograms with the ImageJ program. Sample signals were normalized against 7.51 antibody or a-tubulin signal. Graphics represent three different experiments.
Pharmacological Inhibition of g-Secretase Flies were treated with DAPT and Compound E as described (Micchelli et al., 2003) . 200 ml of a 1 mM stock solution was added to 2 ml food vials prior to egg laying, and progeny were allowed to develop in the presence of drug or DMSO only (as a control) until eclosion. Adult progeny were heat shocked for 1 hr at 37ºC, placed at 25ºC for 12 hr to allow expression of GFP, and examined by fluorescence microscopy to assess relative levels of GFP expression.
Supplemental Data
The Supplemental Data for this article can be found online at http:// www.neuron.org/cgi/content/full/50/3/359/DC1/. Reduced function of the g-secretase components psn, nct, and aph-1 leads to downregulation (downward arrows) of PI3K/Akt and aPKC kinase activities, which in turn causes an upregulation (upward arrows) in their respective downstream kinases GSK3b and PAR-1. Increased activity of these tau kinases facilitates phosphorylation of tau, promoting tau hyperphosphorylation, aggregation, and associated neurotoxicity.
(M) Transgenic aph-1 expression leads to a more pronounced accumulation of phosphorylated PAR-1 at the cell cortex (compare to Figure 6K , top), whereas the shaggy/GSK3b distribution is apparently unaffected (N) (compare to Figure 6J , top). Scale bars: (A)-(F), 100 mm; (I)-(N), 5 mm. Mean 6 SEM, p < 0.001.
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